

INDUSTRY LUNCH SYMPOSIA

Thursday 24<sup>th</sup> February 2011  
Pfizer Australia  
Grand Ballroom  
1215 - 1345



Adrian gained his MB BCh degree from the University of Pretoria in 1984, before completing further medical training, including his M Med degree in 1994.

He is the immediate Past President of the Federation of Infectious Diseases Societies of Southern Africa.

His research interests include antibiotic resistance particularly in respiratory tract and intensive care related infections, including the pharmacokinetics of antibiotics in these settings. He has published related papers on ertapenem and teicoplanin for ESBL and MRSA infections, respectively. Current projects include elucidation of carbapenem resistance mechanisms amongst clinical strains of ICU-acquired *Enterobacteriaceae* and the pharmacokinetics of prolonged infusions of different carbapenems. He serves on the editorial board of several journals and has published 38 papers.

Lunch will be provided in the Grand Ballroom from 1215

Managing the Complicated Patient in an Era of Endemic Resistance

Adrian Brink

Adrian John Brink is currently Head of Clinical Microbiology, Ampath National Laboratory Services, South Africa and Chief Microbiologist at Milpark Hospital, Johannesburg.

He is a lecturer in the Department of Clinical Microbiology and Infectious Diseases at the University of Witwatersrand, Johannesburg.

INDUSTRY BREAKFAST SYMPOSIA

Thursday 24<sup>th</sup> February 2011  
bioMérieux Australia  
Stradbroke/Huntingfield Room  
0700 - 0845



Martin Welker

Dr Martin Welker has worked with MALDI-TOF MS for bacterial characterisation for more than ten years. In the last few years his particular focus was the development of the microbial identification tool, SARAMIS, as part of the team at AnagnosTec. Last year, he has joined BioMérieux as a mass spectrometry Specialist, dedicated to explore new horizons in mass spectrometrical analyses for clinical microbiology.

Anne Beall

Anne has over 22 years of experience in the clinical industry, both at the management level and as a scientist. She is currently working as a Microbiology Lean Workflow Consultant assessing microbiology labs, assisting in the analysis and developing implementation plans for lean workflow processes, space planning, and process change.

Martin will discuss the development of Maldi-Tof and his own personal involvement in the process. He will elaborate on some of the obvious strengths associated with this revolutionary new technology but also talk about its limitations, particularly with respect to antimicrobial susceptibility testing and/or resistance markers.

Anne will follow on from this discussion and look at the real impact of a rapid identification from a Lean Workflow process viewpoint. She will look at and discuss opportunities to further the time gains achieved through Maldi-Tof in other parts of the Laboratory (particularly related to AST).

Breakfast will be served in the Stradbroke/Huntingfield Room from 0700

Thursday 24<sup>th</sup> February 2011  
Merck Sharp and Dohme  
Delacombe Room  
0700 - 0845



Debra Goff

Debra A. Goff, PharmD, FCCP, is an Infectious Disease Specialist and director of the Infectious Diseases Residency program at The Ohio State University Medical Center (OSUMC) in Columbus, Ohio. Dr. Goff is a member of the Antimicrobial Stewardship Program (ASP). She is an Associate Professor at the College of Pharmacy. Dr. Goff received her Bachelor of Pharmacy degree, Doctor of Pharmacy degree, and performed her pharmacy residency at the University of Illinois at Chicago. She practiced at Grant Medical Center for 7 years before joining the Infectious Disease Division at The Ohio State University Medical Center in 1989.

Breakfast will be served in the Delacombe Room from 0700

Antimicrobial Stewardship Programs: How to Make a Difference in Your Hospital

INDUSTRY BREAKFAST SYMPOSIA (Continued)

Friday 25<sup>th</sup> February 2011  
BD Diagnostics  
Stradbroke/Huntingfield Room  
0700 - 0845



Avoiding the Vicious Cycle of Spiralling Empiricism

Michael Towns

Michael Towns, M.D. is currently the WW Vice President of Medical Affairs for BD Diagnostics-Infectious Disease. He has extensive experience in clinical microbiology and infectious diseases, with a special interest in the clinical significance and detection of bloodstream infections, a topic on which he has lectured worldwide. In addition he has published numerous scientific articles and has authored four book chapters in three different infectious disease textbooks, including "Antimicrobial Therapy and Vaccines" by Victor Yu (ed). He is also

a voting member of the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Principles and Practices for Blood Culture, as well as the FDA Microbiology Devices Advisory Panel.

Michael will discuss why blood cultures can be negative in sepsis patients; the best practices for diagnosing bloodstream infections; the availability of rapid technologies (such as Bruker Maldi-Tof) to provide a rapid ID; and the state of PCR technologies to contribute additional information directly from the blood.

Breakfast will be served in the Stradbroke/Huntingfield Room from 0700

Friday 25<sup>th</sup> February 2011  
Bayer Schering Pharma  
Delacombe Room  
0700 - 0845



Bayer HealthCare  
Bayer Schering Pharma

A selection of key peer reviewed journals on antimicrobials published in 2010 will be presented by:

Joseph Doyle, Royal Melbourne Hospital

Emergence of a New Antibiotic Resistance Mechanism in India, Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study.  
Kumarasamy KK, Toleman MA, Walsh TR, et al.  
Lancet Infect Dis 2010; 10: 597-602

Lydia Upjohn, Royal Melbourne Hospital

Foreign Travel Is a Major Risk Factor for Colonization with *Escherichia coli* Producing CTX-M-Type Extended-Spectrum  $\beta$ -Lactamases: a Prospective Study with Swedish Volunteers  
T Tängdén, O Cars, Å Melhus, and E Löwdin  
AAC 2010; 54:3564-3568

Andrew Mahony, Austin Health

Vancomycin-Resistant *Enterococcus* Domination of Intestinal Microbiota is Enabled by Antibiotic Treatment in Mice and Precedes Bloodstream Invasion in Humans.  
Ubeda C, Taur Y, Jenq RR, et al.  
J Clin Invest. 2010; 120:4332-41

Catherine Marshall, Alfred Hospital

Artesunate Versus Quinine in the Treatment of Severe Falciparum malaria in African Children (AQUAMAT): An open-label, Randomized Trial.  
Dondorp AM, Fanello CI, Henkens IC, et al.  
Lancet 2010; 376, 1647-1657

Breakfast will be served in the Delacombe Room from 0700

Saturday 26<sup>th</sup> February 2011  
Immuno  
Stradbroke/Huntingfield Room  
0700 - 0845



*Clostridium difficile* Epidemiology, Guidelines and Laboratory Diagnosis - All in a State of Flux

Fred Tenover, Senior Director for Scientific Affairs, Cepheid United States of America.

Breakfast will be served in the Stradbroke/Huntingfield Room from 0700

Saturday 26<sup>th</sup> February 2011  
AstraZeneca  
Delacombe Room  
0700 - 0845



Tailoring Treatment for the Tricky Ones: Antibiotic Dosing for Difficult Infections

Jason Roberts, Royal Brisbane and Women's Hospital, Queensland

Gram Negative Resistance Pump up the Pumps

Anton Peleg, Alfred Hospital, Victoria

Breakfast will be served in the Delacombe Room from 0700